WB, IP, IHC-P
H
Endogenous
50
Rabbit IgG
#P11511
1588
Product Information
Product Usage Information
Application | Dilution |
---|---|
Western Blotting | 1:1000 |
Immunoprecipitation | 1:50 |
Immunohistochemistry (Paraffin) | 1:4200 |
Storage
Specificity / Sensitivity
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human aromatase protein.
Background
Aromatase is a member of the cytochrome P450 superfamily of enzymes, which are monooxygenases that catalyze reactions involved in drug metabolism and cholesterol and steroid synthesis (1,2). Aromatase is responsible for the conversion of testosterone into 17-β estradiol (2). Aromatase is mainly expressed in the brain (3), ovaries (4), and placenta (5). Aromatase plays an important role in development of the central nervous system during ontogenesis (6,7), gonadal development, and sex differentiation (8,9). Research studies have suggested that inhibition of aromatase may be an effective therapeutic strategy for postmenopausal breast cancers that are estrogen receptor positive (6,10). Mutations in the corresponding aromatase gene are associated with cases of aromatase excess syndrome (AEXS) and aromatase deficiency (AROD) disorders (11-14).
- Harada, N. (1988) Biochem Biophys Res Commun 156, 725-32.
- Chen, S.A. et al. (1988) DNA 7, 27-38.
- Hinshelwood, M.M. et al. (2000) Endocrinology 141, 2050-3.
- Pezzi, V. et al. (2003) J Steroid Biochem Mol Biol 87, 181-9.
- Peruffo, A. et al. (2011) Gen Comp Endocrinol 172, 211-7.
- Montelli, S. et al. (2012) Brain Res 1475, 11-8.
- Kuntz, S. et al. (2003) Cytogenet Genome Res 101, 283-8.
- Ramsey, M. et al. (2007) Differentiation 75, 978-91.
- Hu, Q. et al. (2012) J Med Chem 55, 7080-9.
- Gilani, R.A. et al. (2012) Breast Cancer Res Treat 135, 681-92.
- Ito, Y. et al. (1993) Proc Natl Acad Sci U S A 90, 11673-7.
- Morishima, A. et al. (1995) J Clin Endocrinol Metab 80, 3689-98.
- Carani, C. et al. (1997) N Engl J Med 337, 91-5.
- Fukami, M. et al. (2012) Int J Endocrinol 2012, 584807.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting IP: Immunoprecipitation IHC-P: Immunohistochemistry (Paraffin)
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.